Information and Communications Technology Industry in Latvia

About industry
cover

GRINDEKS JSC

General Information
Registration number: 
40003034935
Year of foundation: 
1991
Industry (NACE 2): 
MANUFACTURING
21 Manufacture of basic pharmaceutical products and pharmaceutical preparations
21.2 Manufacture of pharmaceutical preparations
21.20 Manufacture of pharmaceutical preparations
PROFESSIONAL, SCIENTIFIC AND TECHNICAL ACTIVITIES
72 Scientific research and development
72.1 Research and experimental development on natural sciences and engineering
72.11 Research and experimental development on biotechnology
Head of the company, position: 
Mr Juris Bundulis - Chairman of the Board
Number of employees: 
501 - 1 000
Turnover (EUR):
50 000 001 - ...
2016
50 000 001 - ...
2015
Export volume (EUR):
50 000 001 - ...
2016
50 000 001 - ...
2015
Export countries: 
Azerbaijan
Belarus
Estonia
Georgia
Germany
Japan
Kazakhstan
Latvia
Lithuania
Moldova
Netherlands
Russia
Turkmenistan
Ukraine
United States of America
Uzbekistan
Certificates: 
ISO 9001, ISO 14001, Certificates of Good Manufacturing Practice (GMP) for manufacturing of final dosage forms and active pharmaceutical ingredients, Certificate of Good Laboratory Practice (GLP), Russian ГОСТ (GOST) certificate ISO 9001-2011, OHSAS 18001
Contact Information
Website: 
http://www.grindeks.lv
Address: 
Krustpils street 53, Rīga, LV-1057, Latvia
Phone: 
+371-67083205
+371-67083500
Fax: 
+371-67083505
E-mail: 
grindeks [at] grindeks [dot] lv
Contact person, position: 
Ms Laila Kļaviņa - Head of Communications Department
Languages spoken : 
English
Latvian
Russian
Business Profile and Cooperation Interests
Business profile: 

Our main fields are research, development, manufacturing and sales of original products, generics and active pharmaceutical ingredients. Grindeks specialises in heart and cardiovascular, CNS and anti-cancer medication.

Our range of products covers a successful combination of original products and generics, including original products Mildronate® and Ftorafur® and more than 100 forms of effective and safe generics. Currently, Grindeks produces 25 active pharmaceutical ingredients (API). 

 

Cooperation interests: 

International business development of both APIs in regulated markets (US, EU, Japan, etc.) and finished dosage forms (FDF) in Europe and emerging markets; co-development and out-licensing of existing and new APIs and FDFs; Contract manufacturing of APIs and FDFs (oral, ointment & syrup facilities); chemical and microbiological analytical testing services. 

Target export countries: 
Australia
Azerbaijan
Belarus
Estonia
Georgia
Germany
Japan
Kazakhstan
Lithuania
Moldova
Netherlands
Russia
Turkmenistan
Ukraine
United States of America
Uzbekistan
Images: